The bone-derived fibroblast growth factor-23 (FGF23) is a novel marker of CKD-MBD, that increase progressively with declining renal function [3–10] and markedly increase in end-stage renal disease (ESRD) [6, 10, 11]. This evidence concerns the gene FGF23 and Marchiafava-Bignami disease.